GLP1R and type 2 diabetes mellitus: In contrast, both the semaglutide (T2DM+GLP-1) and dapagliflozin (T2DM+SGLT2i) groups experienced marked reductions in blood glucose levels compared to their pre-treatment values and the untreated T2DM group (p < 0.001).